Loading
companiesCompany
Isarna Therapeutics
Isarna, formerly Antisense Pharma, is a Munich company whose TGF-beta2 antisense drug trabedersen was tested directly into brain tumours in phase 3 for high-grade glioma before the programme moved to eye disease.
Also called: Isarna Therapeutics GmbHAntisense Pharma
Overview
Isarna Therapeutics, founded in Regensburg in 1998 as Antisense Pharma and now based in Munich, develops antisense oligonucleotides against transforming growth factor beta 2. Trabedersen (AP 12009), infused into the tumour, reached the phase 3 SAPPHIRE trial in anaplastic astrocytoma, which was stopped early, and the company has since focused on ophthalmology. Its trials remain on ClinicalTrials.gov under the company as lead sponsor.
Headquarters
Munich, DE
Scorecard
All companies#399of 1244 companies, score 9
- phase 3 +3
- modalities +2
- registry trials +4
0 approved, 1 in phase 3, 0 earlier, 0 targets, 5 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Founded
1998
Phase 3antisense oligonucleotide (per the sponsor's description; form not stated in the registry record)
Trabedersen is an experimental investigational agent whose form is not stated in the registry from Oncotelic in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.
Similar pages
- TrialA Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
- CompanyIonis Pharmaceuticals
Shares Oligonucleotide therapeutics, Pivotal (registrational) trial, Clinical trial.
- CompanyLisata Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
- CompanyDenovo Biopharma
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
- CompanyDiffusion Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
- CompanyPregLem
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Glioma & glioblastoma.
- CompanyMedigene
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
cancers
technologies
drugs
Phase 3antisense oligonucleotide (per the sponsor's description; form not stated in the registry record)